Morison embarks on exports journey with medical marketing operations in Cambodia

Friday, 20 November 2026 00:00 -     - {{hitsCtrl.values.hits}}

 


Morison, a pioneer in Sri Lankan pharmaceutical manufacturing with over 60 years of industrial expertise and a member of the Hemas Group, recently embarked on its landmark exports journey, establishing its own medical marketing operations in Cambodia. 

The first export consignment was shipped to the country on 11 November, 2026, marking a significant milestone and a historic first in the company’s journey of taking home-grown pharmaceuticals to the world.

The endeavour distinguishes Morison as the first Sri Lankan pharma manufacturer to initiate medical marketing operations in a foreign country through its own team of medical representatives. Headed by a Sri Lankan country manager, Morison has already secured 13 product registrations in Cambodia, with another seven currently in the process of being approved.

Reflecting on the significance of this milestone for the Group, Hemas Healthcare Cluster Chairman Murtaza Esufally said: “For the past 70 years, Hemas has been importing pharmaceuticals to Sri Lanka. Therefore, witnessing Hemas-manufactured pharmaceuticals being exported to another country for the first time is a particularly proud moment for us. It marks a significant milestone in our journey and reflects our ambition to take Sri Lankan pharmaceutical manufacturing beyond our shores.”

The inaugural shipment comprised three of Morison’s newly launched niche, novel therapies, carrying the same brand names under which they are marketed in Sri Lanka: EmpaMor (Empagliflozin Tablets 10 mg and 25 mg), BisoMor (Bisoprolol Tablets BP 2.5 mg and 5 mg) and RivoMor (Rivaroxaban Tablets 10 mg and 20 mg).

Speaking on what this milestone means for Morison’s future, Morison Ltd Managing Director Dinesh Athapaththu said: “This milestone marks a significant achievement for Morison. Initiating our first export shipment and launching our very own medical marketing operation in Cambodia is just the commencement of turning a much bigger, long-term exports roadmap into a reality.”

Cambodia’s market of approximately 18 million people is currently valued at nearly $ 350 million and depends on imports for nearly 95% of its pharmaceutical needs. The country operates in line with WHO GMP guidelines, making it a natural first destination for medicines manufactured to international standards in Sri Lanka.

The timing of the first shipment also carries a special significance for Morison. Exactly four years ago, on 11 November, 2022, the company announced its entry into the branded generics space in Sri Lanka, making 11 November a special day in the Morison calendar.

Leading the Cambodian operations as Country Manager is Prabuddha Walpita, previously Senior Manager Commercial at Morison. Having been with the company for the last 10 years, he has built his career at Morison, rising through the ranks across a variety of roles.

Commenting on his appointment, Walpita said: “Having joined Morison as a fresh graduate back in 2016, over the last 10 years I have seen the company transition from the home of Morison’s Gripe Mixture and Morison’s Lacto Calamine to a respected branded generics pharma manufacturer among the medical fraternity, and now to one that is expanding its horizons to the global market. I am truly grateful to have been entrusted with this new challenge. I am excited to take our own pharma brands, built right here in Sri Lanka, to the Cambodian market, navigating any challenges that may come along the way.”

Having entered the branded generics segment just four years ago, the company has already made a significant footprint in the diabetes space, with EmpaMor becoming the highest-selling empagliflozin brand within two years of its launch. Morison has since expanded into cardiovascular products, where it continues to gain traction, supported by its new state-of-the-art pharmaceutical manufacturing facility in Homagama.

COMMENTS